Servier shared a post on LinkedIn:
“We are pleased to announce that we have entered into a definitive agreement with Day One Biopharmaceuticals to expand our rare oncology portfolio and pipeline. This acquisition will build our presence in glioma treatments and is in line with our Servier2030 ambition.
The combination of Day One Biopharmaceuticals’ scientific expertise with our established global capabilities, will aim to advance a shared commitment to delivering innovative new therapies to patients with rare cancer specifically in glioma.
Learn more about this potential acquisition.
Important or required information is provided.”
Other articles about Servier on OncoDaily.